Vote Scores
Filings read through

Inhibikase Therapeutics, Inc.: how funds voted at the meeting of 26 Jun 2026

Ticker
IKT
Meeting
Season
year to 30 June 2026
Filers reporting
134
Ballot items
6

134 filers on Form N-PX reported votes at the Inhibikase Therapeutics, Inc. meeting of 26 Jun 2026. The records fall into 6 ballot items. The page lists them in ballot order: items of the company first, then proposals from security holders. Each bar shows how the reporting filers split. It is not the result of the meeting.

If the reporting person has not received confirmation of the actual number of votes cast prior to filing a report on Form N-PX, the numbers reported may reflect the number of shares instructed to be cast. A reporting person is not required to amend a previously filed Form N-PX report if the reporting person subsequently receives confirmation of the actual number of votes cast.

The words of the SEC. Source: Form N-PX and its instructions, Special Instructions D.5 and D.8, copied on .

The words of this site: the filer writes each filing. The SEC does not say that it checked the votes. A lender does not vote shares that are on loan. A later filing (Form N-PX/A) can replace an earlier filing, and the site uses the latest.

The figures on this page count the filers that report on Form N-PX and the shares they reported. They do not count all votes cast at the meeting.

The page gives records. It gives no investment advice and no advice on how to vote.

Season on this page: year to 30 June 2026. Filings read through . How the figures are made

The ballot

ForAgainstAbstain, withhold or otherAmber tick: the part cast against management

  1. Item 1: Director elections

    2 nominees. 46.1% of the reported votes are for. 37 filers withheld from or voted against at least one nominee.

    178 vote records from 48 filers. 16 of the 48 filers that marked the item voted against management.

    • Positions of 26 fund families
    • For 9
    • Abstain or withhold 10
    • Split or no vote 7
    • Against management 10
  2. Item 2: Advisory vote on executive pay (say-on-pay)

    213 vote records from 131 filers. 95 of the 124 filers that marked the item voted against management. 7 filers gave no management mark.

    • Positions of 32 fund families
    • For 5
    • Against 27
    • Against management 27
  3. Item 3: Frequency of the say-on-pay vote

    One year: 116 filers. For: 5 filers. Not applicable: 2 filers. Against: 1 filer. 1-year: 1 filer. Abstain: 1 filer.

    199 vote records from 130 filers. 0 of the 124 filers that marked the item voted against management. 6 filers gave no management mark.

    • Positions of 32 fund families
    • For 1
    • Split or no vote 31
  4. Item 4: Audit-related items (auditor ratification)

    85 vote records from 48 filers. 0 of the 48 filers that marked the item voted against management.

    • Positions of 26 fund families
    • For 26
  5. Item 5: COMPENSATION: management items

    The company's items in this category are shown together, because filers word and number them differently.

    90 vote records from 49 filers. 45 of the 49 filers that marked the item voted against management.

    • Positions of 26 fund families
    • Against 26
    • Against management 25
  6. Item 6: CORPORATE GOVERNANCE: management items

    The company's items in this category are shown together, because filers word and number them differently.

    77 vote records from 44 filers. 4 of the 44 filers that marked the item voted against management.

    • Positions of 25 fund families
    • For 21
    • Against 4
    • Against management 3

Positions of the fund families

A position is not the vote of each fund. The position of a family is the way most of the shares reported by its filers were voted. Funds of one family can vote in different ways.

KeyForAgainstAbstain or withholdSplit or no voteAgainst management

Fund families at Inhibikase Therapeutics, Inc., meeting of 26 Jun 2026Families in name order. "Abstain" includes withhold. "Split" includes no vote. "No report" means that no filer of the family listed the item.
Fund family2. Say-on-pay3. Pay-vote frequency4. Auditor
AllianceBernsteinAgainst, against managementSplitNo report
American CenturyAgainst, against managementSplitFor
BlackRock and iSharesAgainst, against managementSplitFor
BNY MellonForSplitNo report
Brighthouse FundsForForFor
Charles SchwabAgainst, against managementSplitFor
DWSAgainst, against managementSplitFor
EquitableAgainst, against managementSplitFor
FidelityAgainst, against managementSplitFor
Global XAgainst, against managementSplitFor
Goldman SachsForSplitFor
Guggenheim and RydexAgainst, against managementSplitFor
InvescoAgainst, against managementSplitNo report
J.P. MorganForSplitFor
John Hancock and ManulifeAgainst, against managementSplitFor
Lincoln FinancialAgainst, against managementSplitFor
Morgan Stanley, Eaton Vance and CalvertAgainst, against managementSplitFor
NationwideAgainst, against managementSplitFor
Neuberger BermanAgainst, against managementSplitNo report
Northern Trust and FlexSharesAgainst, against managementSplitFor
Nuveen and TIAAAgainst, against managementSplitFor
Pacific Life fundsAgainst, against managementSplitFor
PGIM and PrudentialAgainst, against managementSplitNo report
PrincipalAgainst, against managementSplitFor
ProShares and ProFundsAgainst, against managementSplitFor
Russell InvestmentsAgainst, against managementSplitNo report
SEIAgainst, against managementSplitFor
State Street and SPDRAgainst, against managementSplitFor
T. Rowe PriceAgainst, against managementSplitFor
VanguardAgainst, against managementSplitFor
Victory CapitalAgainst, against managementSplitFor
VoyaForSplitFor

Questions

How many filers reported votes at the Inhibikase Therapeutics, Inc. meeting?
134 Form N-PX filers reported votes at the meeting of 26 Jun 2026. On say-on-pay, 95 of 124 filers that marked the item voted against management (76.6%).
Is this the result of the meeting?
No. The page counts the filers that report on Form N-PX, and the shares they reported. Inhibikase Therapeutics, Inc. reports the result of a vote on Form 8-K.
Why does the page show counts only for director elections?
A director record names the nominee. This site has no page and no row about a person. For director elections it keeps the number of nominees and the split of votes.

Provenance: SEC EDGAR, Form N-PX and N-PX/A filings that list Inhibikase Therapeutics, Inc. with a meeting date within three days of 26 Jun 2026. A proposal title is the most common wording among filers. Where a wording can name a person, the SEC category is shown. The filers wrote the filings. Filings read through .